ClinicalTrials.gg
CompletedNCT05192941V-DIFFERENCEUpdated Apr 14, 2026Results posted

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

A Phase 4 interventional study of Inclisiran Sodium and Placebo in Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 136 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,770
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Enrollment
5th of 24
1,770 · median 375
Started
2022
the only one that year
Phase 4
7 of 24
3 open now
Registered
12th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 4, and was the 12th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia

Read the detailed description

This was a double-blind, placebo-controlled multicenter study in adult participants with very high or high cardiovascular risk who did not meet their individual LDL-C target despite being treated with their individual maximum tolerated dose (MTD) of a statin, and if applicable, further Lipid-Lowering Therapy (LLT).

The purpose of this study was to demonstrate the superiority of inclisiran compared to placebo, both on top of ongoing individually optimized LLT, on reaching a participant's LDL-C target (\< 55 mg/dL or \< 70 mg/dL, depending on the cardiovascular risk category), according to the 2019 ESC/EAS guidelines for the management of dyslipidemias as well as on patient-relevant safety, tolerability outcomes and quality of life.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Inclisiran
  • rosuvastatin
  • PCSK9
  • dyslipidemia
  • angina pectoris
  • peripheral artery disease
  • cardiovascular disease
  • LDL-C
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

  1. Written must be obtained before any assessment is performed.
  2. Male or female participants ≥18 years of age.
  3. Participants categorized as very high or high CV risk, as defined below:

    •Very high risk participants with at least one of the following: A. Documented Atherosclerotic Cardiovascular Disease (ASCVD) i) Acute Coronary Syndrome: Unstable angina or myocardial infarction ii) Stable angina iii) Unequivocally documented ASCVD upon prior imaging v) Stroke and (TIA) vi) Peripheral Artery Disease (PAD) B. Diabetes mellitus (DM) with target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), or at least ≥ 3 major risk factors, or early onset of Type 1 DM of long duration (> 20 years) C. A calculated SCORE2 ≥ 7.5% for age \< 50 years; SCORE2 ≥ 10% for age 50-69 years; SCORE2-OP ≥ 15% for age ≥ 70 years to estimate 10-year risk of fatal and non-fatal CVD D. Pre-existing diagnosis of heterozygous familial hypercholesterolemia (HeFH) with ASCVD or with another major risk factor.

    OR

    •High risk participants with at least one of the following: A. Markedly elevated single risk factors, in particular total cholesterol > 310 mg/dL, LDL-C > 190 mg/dL, or blood pressure ≥ 180/110 mmHg B. Pre-existing diagnosis of HeFH without other major risk factors C. DM without target organ damage (defined as microalbuminuria, retinopathy, or neuropathy), with DM duration ≥ 10 years or other additional risk factor D. Moderate chronic kidney disease ( 30-59 mL/min/1.73m2) E. A calculated SCORE2 2.5 to \<7.5% for age under 50 years; SCORE2 5 to \<10% for age 50-69 years; SCORE2-OP 7.5 to \<15% for age ≥70 years to estimate 10-year risk of fatal and non-fatal CVD as defined by the cardiovascular risk categories in the 2019 ESC/EAS guideline (Mach et al 2020)

  4. LDL-C levels:

    1. in participants with very high cardiovascular risk: serum LDL-C ≥55 mg/dL
    2. in participants with high cardiovascular risk: serum LDL-C ≥70 mg/dL
  5. Participant on a stable dose of a statin for ≥ 30 days.
  6. Up to approximately 20% of total participants can be on a stable dose (for ≥ 30 days prior to screening) of another LLT on top of statin such as a cholesterol absorbing inhibitor or a bile acid sequestrant, or alternatively, an adenosine triphosphate citrate lyase (ACL) inhibitor, as indicated.
  7. Fasting triglyceride \< 400 mg/dL.

    At Baseline:

  8. Fasting triglyceride \< 400 mg/dL.
  9. Before randomization, despite being treated with the individual MTD of a statin for ≥ 30 days and, if applicable, with another LLT on top of statin (stable for ≥ 30 days),

    1. in participants with very high cardiovascular risk: serum LDL-C ≥ 55mg/dL.
    2. in participants with high cardiovascular risk: serum LDL-C ≥ 70mg/dL.

Key Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this study.

  1. Severe concomitant non-CV disease that is expected to reduce to less than 2 years at screening or baseline visit.
  2. Participants on more than one other lipid-lowering drug on top of statin at screening visit.
  3. Pre-existing diagnosis of homozygous familial hypercholesterolemia at screening or baseline visit.
  4. Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome at screening or baseline visit.
  5. Previous (within 90 days of screening), current or planned treatment with a monoclonal antibody (mAb) directed towards PCSK9 (e.g. evolocumab, alirocumab) at screening or baseline visit.
  6. Previous exposure to inclisiran or any other non-mAb PCSK9 targeted therapy, either as an or marketed drug within 2 years prior to screening or baseline visit.
  7. Previous, current or planned treatment with LDL-apheresis at screening or baseline visit.
  8. Participants with known intolerance to rosuvastatin at screening or baseline visit.
  9. History of to any of the study treatments, inclisiran or rosuvastatin, or its or to drugs of similar chemical classes at screening or baseline visit.
  10. Participants taking gemfibrozil at screening or baseline visit.
  11. Liver and CK: (a) Active liver disease defined as any current infectious, neoplastic, or metabolic pathology of the liver or (b) unexplained (ALT), aspartate aminotransferase (AST) elevation >3x , or total elevation > 2x ULN (except for participants with Gilbert's syndrome), or (c) creatine kinase (CK) >5x ULN at screening or baseline visit.
  12. Participant with severe renal impairment defined by eGFR \<30 mL/min/1.73m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at screening or baseline visit.
  13. Acute coronary syndrome, ischemic stroke or TIA, coronary revascularization or peripheral arterial revascularization procedure or amputation due to atherosclerotic disease \< 3 months prior to the screening or baseline visit.
  14. Planned or expected cardiac, cerebrovascular or peripheral artery surgery or coronary revascularization within the study duration.
  15. Heart failure (NYHA) class IV at screening or baseline visit.
  16. History of that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy (excluding systemic therapies given to prevent cancer recurrence eg: hormonotherapy for prostate or breast cancer) during the 3 years prior to screening or baseline visit.
  17. Participant with myopathy at screening or baseline visit.
  18. Participant receiving concomitant ciclosporin at screening or baseline visit.
  19. Participants that are predisposed to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).
  20. Participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose-malabsorption.
  21. Unwillingness or inability (e.g. physical or cognitive) to comply with study procedures (including study visits, fasting blood draws and compliance with study treatment regimens), and medication administration (injections) and schedule. Participant should be able and willing to read, understand and answer questionnaires.
  22. Any surgical or medical condition, which in the opinion of the investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study at screening or baseline visit.
  23. Use of other investigational drugs within 5 half-lives, 30 days or until the expected pharmacodynamic effect has returned to baseline (e.g. biologics), whichever is longer or longer if required by local regulation, prior to screening visit.
  24. Pregnant or nursing (lactating) women at screening or baseline visit.
  25. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment, which includes rosuvastatin, and for 5 days (= 5 times the terminal half-life of rosuvastatin) after stopping medication. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
    • Use of oral, (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \< 1%), for example hormone vaginal ring or transdermal hormone contraception.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

Women are considered if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women are considered not of child bearing potential if they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessments and she is considered not of child bearing potential.

If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the local ICF.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,770 participants (actual)

Study arms

  • Experimental
    Inclisiran

    Inclisiran sodium 300 mg s.c. + open label rosuvastatin Open label study treatment rosuvastatin: participants receive an individually optimized rosuvastatin therapy for reaching the individual LDL-C target and tolerability

    Drug: Inclisiran Sodium

  • Placebo comparator
    Placebo

    Corresponding placebo + open label rosuvastatin Open label study treatment rosuvastatin: participants receive an individually optimized rosuvastatin therapy for reaching the individual LDL-C target and tolerability

    Drug: Placebo

Interventions

  • Subcutaneously injected on Day 1, Day 90, and Day 270

    Also known as: KJX839

  • DrugPlacebo

    Placebo to inclisiran 300 mg subcutaneously

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)

    Number of participants achieving individual Low-density Lipoprotein Cholesterol (LDL-C) target (\< 55 mg/dL or \< 70 mg/dL) at Day 90. The individual LDL-C target of the participants was determined according to their most recent individual cardiovascular risk category. A larger proportion of participants indicates a superior outcome.

    Time frame: Day 90

Secondary outcomes

  1. Relative Change From Baseline to Mean LDL-C Level Over the Double-blind Treatment Period

    Relative (percentage) change from baseline in Low-density Lipoprotein Cholesterol (LDL-C) level averaged over the double-blind treatment period

    Time frame: Baseline to Day 360

  2. Number of Participants Experiencing at Least One Muscle-related Adverse Event From Day 1 to Day 360

    The number of participants who experienced at least one muscle-related adverse event, defined as Standardized MedDRA Queries (SMQ) rhabdomyolysis / myopathy from Day 1 to Day 360. All muscle-related adverse events occurring between first dose of double-blind treatment and earliest date out of visit Day 360, death date and last contact date are considered.

    Time frame: Day 1 to Day 360

  3. Number of Participants Experiencing Self-reported Pain

    Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain. The percentage of days with pain for each participant is calculated as number of days with pain divided by the total number of days where diary was completed, multiplied by 100. Diary data between the first dose of double-blind treatment up to the minimum of last contact date and Day 360 visit are considered.

    Time frame: Day 1 to Day 360

  4. Annualized Number of Days With Pain

    Annualized rate refers to the estimated number of days with pain per year. Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain.

    Time frame: Day 1 to Day 360

  5. Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score Over the Double-blind Treatment Period

    The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.

    Time frame: Baseline to Day 360

  6. Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score Over the Double-blind Treatment Period

    The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.

    Time frame: Baseline to Day 360

  7. Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score From Baseline to Day 360.

    The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain severity score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.

    Time frame: Baseline to Day 360

  8. Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score From Baseline to Day 360

    The SF-BPI is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain interference score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.

    Time frame: Baseline to Day 360

07

Results

Posted Apr 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneInclisiranPlacebo
Started898872
Full analysis set (fas)898872
Safety set (saf)900870
Completed880845
Not completed1827
Withdrew: Subject decision815
Withdrew: Death65
Withdrew: Adverse event34
Withdrew: Lost to follow-up12
Withdrew: Physician decision01

Outcome measures

PrimaryNumber of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)

Number of participants achieving individual Low-density Lipoprotein Cholesterol (LDL-C) target (\< 55 mg/dL or \< 70 mg/dL) at Day 90. The individual LDL-C target of the participants was determined according to their most recent individual cardiovascular risk category. A larger proportion of participants indicates a superior outcome.

Time frame:
Day 90
Reported as:
Count of participants · Participants
Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)
ParticipantsInclisiranPlacebo
Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)752266
Statistical analysis
  • Inclisiran vs Placebo · Regression, Logistic · p = <0.0001 (One-sided p-value reported.) · Odds ratio (or): 12.09 · 95% CI 9.59 to 15.24Statistical analysis is based on all participants in the Full Analysis Set (inclisiran arm=898; placebo arm=872).
SecondaryRelative Change From Baseline to Mean LDL-C Level Over the Double-blind Treatment Period

Relative (percentage) change from baseline in Low-density Lipoprotein Cholesterol (LDL-C) level averaged over the double-blind treatment period

Time frame:
Baseline to Day 360
Reported as:
Least squares mean · percent change in LDL-C
Relative Change From Baseline to Mean LDL-C Level Over the Double-blind Treatment Period
percent change in LDL-CInclisiranPlacebo
Relative Change From Baseline to Mean LDL-C Level Over the Double-blind Treatment Period-59.45 (-60.79 to -58.11)-24.31 (-25.68 to -22.93)
Statistical analysis
  • Inclisiran vs Placebo · Mixed Models Analysis · p = <.0001 (One-sided p-value reported.) · Least squares mean: -35.14 · 95% CI -37.07 to -33.22
SecondaryNumber of Participants Experiencing at Least One Muscle-related Adverse Event From Day 1 to Day 360

The number of participants who experienced at least one muscle-related adverse event, defined as Standardized MedDRA Queries (SMQ) rhabdomyolysis / myopathy from Day 1 to Day 360. All muscle-related adverse events occurring between first dose of double-blind treatment and earliest date out of visit Day 360, death date and last contact date are considered.

Time frame:
Day 1 to Day 360
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Muscle-related Adverse Event From Day 1 to Day 360
ParticipantsInclisiranPlacebo
Number of Participants Experiencing at Least One Muscle-related Adverse Event From Day 1 to Day 360107167
Statistical analysis
  • Inclisiran vs Placebo · Regression, Logistic · p = <.0001 (One-sided p-value reported.) · Odds ratio (or): 0.57 · 95% CI 0.43 to 0.74
SecondaryNumber of Participants Experiencing Self-reported Pain

Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain. The percentage of days with pain for each participant is calculated as number of days with pain divided by the total number of days where diary was completed, multiplied by 100. Diary data between the first dose of double-blind treatment up to the minimum of last contact date and Day 360 visit are considered.

Time frame:
Day 1 to Day 360
Reported as:
Count of participants · Participants
Number of Participants Experiencing Self-reported Pain
ParticipantsInclisiranPlacebo
Percentage of days with pain: 0%14398
Percentage of days with pain: >0-20%189177
Percentage of days with pain: >20-40%4571
Percentage of days with pain: >40-60%6044
Percentage of days with pain: >60-80%4848
Percentage of days with pain: >80%409432
Percentage of days with pain: Missing42
SecondaryAnnualized Number of Days With Pain

Annualized rate refers to the estimated number of days with pain per year. Self-reported pain is reported at its worst in the last 24 h on a numeric rating scale from 0 (no pain) to 10 (pain as bad as you can imagine). Days with a score of 0 are considered as days without pain.

Time frame:
Day 1 to Day 360
Reported as:
Least squares mean · Days
Annualized Number of Days With Pain
DaysInclisiranPlacebo
Annualized Number of Days With Pain198.63 (180.46 to 218.62)214.51 (194.63 to 236.42)
Statistical analysis
  • Inclisiran vs Placebo · Negative binomial model · p = 0.1349 (One-sided p-value reported.) · Ratio of rates: 0.93 · 95% CI 0.81 to 1.06
SecondaryAverage Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score Over the Double-blind Treatment Period

The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.

Time frame:
Baseline to Day 360
Reported as:
Least squares mean · score on a scale
Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score Over the Double-blind Treatment Period
score on a scaleInclisiranPlacebo
Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score Over the Double-blind Treatment Period-0.21 (-0.30 to -0.13)-0.10 (-0.19 to -0.02)
Statistical analysis
  • Inclisiran vs Placebo · Mixed Models Analysis · p = 0.0389 (One-sided p-value reported.) · Least squares mean: -0.11 · 95% CI -0.23 to 0.01
SecondaryAverage Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score Over the Double-blind Treatment Period

The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.

Time frame:
Baseline to Day 360
Reported as:
Least squares mean · score on a scale
Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score Over the Double-blind Treatment Period
score on a scaleInclisiranPlacebo
Average Absolute Change From Baseline in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score Over the Double-blind Treatment Period-0.06 (-0.14 to 0.02)0.05 (-0.03 to 0.13)
Statistical analysis
  • Inclisiran vs Placebo · Mixed Models Analysis · p = 0.0285 (One-sided p-value reported.) · Least squares mean: -0.11 · 95% CI -0.22 to 0.00
SecondaryNumber of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score From Baseline to Day 360.

The Short-Form Brief Pain Inventory (SF-BPI) is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain severity score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 4 items in the pain severity domain (questionnaire items number 3, 4, 5, 6). The derived pain severity score ranged between 0 (no pain) and 10 (pain as bad as you can imagine), with larger values indicating a higher level of pain severity (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain severity score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (3 of 4 \[pain severity\] ), the missing items were imputed using the mean score of the non-missing item scores.

Time frame:
Baseline to Day 360
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score From Baseline to Day 360.
ParticipantsInclisiranPlacebo
Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Severity Score From Baseline to Day 360.123104
Statistical analysis
  • Inclisiran vs Placebo · Regression, Logistic · p = 0.0993 (One-sided p-value reported.) · Odds ratio (or): 1.20 · 95% CI 0.91 to 1.58Statistical analysis is based on all participants (inclisiran arm=898; placebo arm=872)
SecondaryNumber of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score From Baseline to Day 360

The SF-BPI is a self-administered standardized fifteen items questionnaire that assesses how pain interferes with or influences a participant's life. The query period covers the past 24 hours and takes 5 minutes for the participant to complete. The pain interference score was derived for each visit between screening and EOT/EOS (Day 360) as the average over the 7 items in the pain interference domain (questionnaire items number 9A through 9G). The derived pain interference score ranged between 0 (does not interfere) and 10 (completely interferes), with larger values indicating a higher level of pain interference (worse outcome). A clinically relevant change is defined by a reduction from baseline in SF-BPI pain interference score by at least 2 points. If there was missing data for a participant and the available data was more than 50% for the corresponding domain (4 of 7 \[pain interference\] ), the missing items were imputed using the mean score of the non-missing item scores.

Time frame:
Baseline to Day 360
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score From Baseline to Day 360
ParticipantsInclisiranPlacebo
Number of Participants With Clinically Relevant Change in Short-Form Brief Pain Inventory (SF-BPI) Pain Interference Score From Baseline to Day 3608770
Statistical analysis
  • Inclisiran vs Placebo · Regression, Logistic · p = 0.0991 (One-sided p-value reported.) · Odds ratio (or): 1.24 · 95% CI 0.89 to 1.71Statistical analysis is based on all participants (inclisiran arm=898; placebo arm=872)

Adverse events

Collected over Treatment-emergent adverse events were reported in the clinical database from first dose of study treatment until the study completion visit, up to a planned maximum duration of 360 days.. Non-serious events are listed at a 1.999% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran6/900 (0.7%)148/900 (16.4%)416/900 (46.2%)
Placebo5/870 (0.6%)148/870 (17%)462/870 (53.1%)
Total11/1,770 (0.6%)296/1,770 (16.7%)878/1,770 (49.6%)
Most frequent serious events
Showing 10 of 229
Most frequent serious events
EventInclisiranPlaceboTotal
OsteoarthritisMusculoskeletal and connective tissue disorders4/90012/87016/1770
Atrial fibrillationCardiac disorders12/9005/87017/1770
Angina pectorisCardiac disorders5/9009/87014/1770
Angina unstableCardiac disorders7/9002/8709/1770
Coronary artery diseaseCardiac disorders7/9005/87012/1770
Peripheral arterial occlusive diseaseVascular disorders7/9006/87013/1770
PneumoniaInfections and infestations6/9004/87010/1770
Chest painGeneral disorders and administration site conditions5/9001/8706/1770
Ischaemic strokeNervous system disorders1/9004/8705/1770
Acute kidney injuryRenal and urinary disorders2/9004/8706/1770
Most frequent other events
Showing 10 of 23
Most frequent other events
EventInclisiranPlaceboTotal
MyalgiaMusculoskeletal and connective tissue disorders49/90082/870131/1770
NasopharyngitisInfections and infestations74/90079/870153/1770
COVID-19Infections and infestations55/90055/870110/1770
Diabetes mellitus inadequate controlMetabolism and nutrition disorders55/90049/870104/1770
Back painMusculoskeletal and connective tissue disorders52/90046/87098/1770
DiarrhoeaGastrointestinal disorders28/90050/87078/1770
ArthralgiaMusculoskeletal and connective tissue disorders27/90048/87075/1770
ConstipationGastrointestinal disorders19/90043/87062/1770
NauseaGastrointestinal disorders16/90041/87057/1770
HypertensionVascular disorders42/90032/87074/1770

Baseline characteristics

Baseline Characteristics are based on the Full analysis set (FAS)

Age, Categorical
Age, Categorical(Participants)InclisiranPlaceboTotal
<=18 years000
Between 18 and 65 years462443905
>=65 years436429865
Age, Continuous
Age, Continuous(years)InclisiranPlaceboTotal
Mean63.8 ± 9.6963.7 ± 9.9963.7 ± 9.84
Sex: Female, Male
Sex: Female, Male(Participants)InclisiranPlaceboTotal
Female273262535
Male6256101235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)InclisiranPlaceboTotal
White8708451715
Black or African American145
Asian224
Native Hawaiian or Other Pacific Islander101
American Indian or Alaska Native022
Unknown224
Not Reported221739
08

Study locations

136 sites
  • Novartis Investigative Site
    Sofia, Bulgaria 1202, Bulgaria
  • Novartis Investigative Site
    Burgas, Burgas 8000, Bulgaria
  • Novartis Investigative Site
    Burgas, 8001, Bulgaria
  • Novartis Investigative Site
    Gabrovo, 5300, Bulgaria
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Rousse, 7000, Bulgaria
  • Novartis Investigative Site
    Sofia, 1233, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Sofia, 1618, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, 6000, Bulgaria
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Veliko Tarnovo, 5000, Bulgaria
  • Novartis Investigative Site
    Chlumec nad Cidlinou, Chlumec Nad Cidlinou 503 51, Czechia
  • Novartis Investigative Site
    Přerov, Olomouc Region 750 02, Czechia
  • Novartis Investigative Site
    Hlučín, 748 01, Czechia
  • Novartis Investigative Site
    Hodonín, 695 01, Czechia
  • Novartis Investigative Site
    Mělník, 276 01, Czechia
  • Novartis Investigative Site
    Olomouc, 772 00, Czechia
  • Novartis Investigative Site
    Olomouc, 779 00, Czechia
  • Novartis Investigative Site
    Pardubice, 532 03, Czechia
  • Novartis Investigative Site
    Slaný, 274 01, Czechia
  • Novartis Investigative Site
    Trutnov, 460 63, Czechia
  • Novartis Investigative Site
    Pärnu, 80018, Estonia
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Tartu, 50406, Estonia
  • Novartis Investigative Site
    Amiens, 80054, France
  • Novartis Investigative Site
    Chambéry, 73000, France
  • Novartis Investigative Site
    Le Chesnay, 78150, France
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Marseille, 13005, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Valenciennes, 59300, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Stuttgart, Baden-Wurttemberg 70376, Germany
  • Novartis Investigative Site
    Lichtenfels, Bavaria 96215, Germany
  • Novartis Investigative Site
    Muehldorf Am Inn, Bavaria 84453, Germany
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
  • Novartis Investigative Site
    Nuremberg, Bavaria 90402, Germany
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60594, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 65929, Germany
  • Novartis Investigative Site
    Langen, Hesse 63225, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Hanover, Lower Saxony 30159, Germany
  • Novartis Investigative Site
    Hanover, Lower Saxony 30449, Germany
  • Novartis Investigative Site
    Winsen, Lower Saxony 21423, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 51065, Germany
  • Novartis Investigative Site
    Essen, North Rhine-Westphalia 45355, Germany
  • Novartis Investigative Site
    Löhne, North Rhine-Westphalia 32584, Germany
  • Novartis Investigative Site
    Kaiserslautern, Rhineland-Palatinate 67655, Germany
  • Novartis Investigative Site
    Saint Ingbert, Saarland 66386, Germany
  • Novartis Investigative Site
    Bad Gottleuba, Saxony 01816, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01099, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Schleswig, Schleswig-Holstein 24837, Germany
  • Novartis Investigative Site
    Bad Homburg, 61348, Germany
  • Novartis Investigative Site
    Bad Krozingen, 79189, Germany
  • Novartis Investigative Site
    Bad Oeynhausen, 32545, Germany
  • Novartis Investigative Site
    Bamberg, 96049, Germany
  • Novartis Investigative Site
    Berlin, 10367, Germany
  • Novartis Investigative Site
    Berlin, 10559, Germany
  • Novartis Investigative Site
    Berlin, 10787, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigative Site
    Bremen, 28277, Germany
  • Novartis Investigative Site
    Coburg, 96450, Germany
  • Novartis Investigative Site
    Cologne, 51069, Germany
  • Novartis Investigative Site
    Dessau, 06846, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duisburg, 47051, Germany
  • Novartis Investigative Site
    Erfurt, 99089, Germany
  • Novartis Investigative Site
    Erfurt, 99097, Germany
  • Novartis Investigative Site
    Essen, 45277, Germany
  • Novartis Investigative Site
    Essen, 45355, Germany
  • Novartis Investigative Site
    Essen, 45359, Germany
  • Novartis Investigative Site
    Fulda, 36037, Germany
  • Novartis Investigative Site
    Gelnhausen, 63571, Germany
  • Novartis Investigative Site
    Gladbeck, 45968, Germany
  • Novartis Investigative Site
    Hamburg, 22041, Germany
  • Novartis Investigative Site
    Hamburg, 22607, Germany
  • Novartis Investigative Site
    Haßloch, 67454, Germany
  • Novartis Investigative Site
    Hennigsdorf, 16761, Germany
  • Novartis Investigative Site
    Hoyerswerda, 02977, Germany
  • Novartis Investigative Site
    Kassel, 34121, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Lüneburg, 21339, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Mannheim, 68165, Germany
  • Novartis Investigative Site
    Markkleeberg, 04416, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany

Showing the first 100 of 136 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Landmesser U, Laufs U, Schatz U, Winzer EB, Nowak B, Kassner U, Gouni-Berthold I, Esteban A, Lubyayi L, Krueger A, Streich JH, Hentschke C, Achouba A, Banach M. Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran's early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia. Am Heart J. 2025 Nov;289:117-126. doi: 10.1016/j.ahj.2025.05.014. Epub 2025 May 26. PubMed 40436308 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jun 2024, 26 months.

Results were first posted in Apr 2026, 1 year 10 months after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Jan 14, 2022
StartActual
Apr 8, 2022
Primary completionActual
Jun 11, 2024
CompletionActual
Mar 19, 2025
Results first posted
Apr 14, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05192941
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Apr 8, 2022
Primary completion
Jun 11, 2024
Completion
Mar 19, 2025
Results posted
Apr 14, 2026
Last update
Apr 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion